-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 CtNLPlFlq2aXCNyTdsZFEc5fuo+jFKJfkkOwYRyK2TIc4qViIatF+2X7753DqQBA
 OFcUxqvBcnQhy+hu49tkrg==

<SEC-DOCUMENT>0001297077-07-000049.txt : 20071023
<SEC-HEADER>0001297077-07-000049.hdr.sgml : 20071023
<ACCEPTANCE-DATETIME>20071023162714
ACCESSION NUMBER:		0001297077-07-000049
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20071022
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
FILED AS OF DATE:		20071023
DATE AS OF CHANGE:		20071023

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHAMPIONS BIOTECHNOLOGY, INC.
		CENTRAL INDEX KEY:			0000771856
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				521401755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17263
		FILM NUMBER:		071185871

	BUSINESS ADDRESS:	
		STREET 1:		2200 WILSON BLVD
		STREET 2:		SUITE 102-316
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22201
		BUSINESS PHONE:		703-526-0400

	MAIL ADDRESS:	
		STREET 1:		2200 WILSON BLVD.
		STREET 2:		SUITE 102-316
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS SPORTS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERNATIONAL GROUP INC
		DATE OF NAME CHANGE:	19860319
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cbi8k-sidransky_chairman.htm
<TEXT>
<html>
<head><meta content="text/html; charset=iso-8859-1">
<title>UNITED STATES</title>
</head>

<body >
<ul>
</ul>

<p>
<p align="center">
<b>UNITED STATES</b><br><b>SECURITIES AND EXCHANGE
COMMISSION</b><br><font size="2"><b>Washington, D.C.
20549</b></font><p align="center">
<b>FORM 8-K</b><p align="center">
<b>CURRENT REPORT</b><br><font size="2"><b>Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934</b></font><p align="center">
<font size="2">Date of Report (Date of earliest event
reported)</font><br><font size="2">October 22, 2007</font><p align="center">
<b>CHAMPIONS BIOTECHNOLOGY, INC</b>.<br><font size="2">(Exact name of registrant
as specified in its charter)</font></p align="center">
<div align="center" style="position:relative; left: 0"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="173.333290" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Delaware</font></p align="center">
</td>
<td width="149.333296" colspan="1" rowspan="1" >
<p align="center">
<font size="2">0-17263</font></p align="center">
</td>
<td width="167.999958" colspan="1" rowspan="1" >
<p align="center">
<font size="2">52-1401755</font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="173.333290" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(State of other jurisdiction</font></p align="center">
</td>
<td width="149.333296" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(Commission</font></p align="center">
</td>
<td width="167.999958" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(IRS Employer</font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="173.333290" colspan="1" rowspan="1" >
<p align="center">
<font size="2">of incorporation)</font></p align="center">
</td>
<td width="149.333296" colspan="1" rowspan="1" >
<p align="center">
<font size="2">File Number)</font></p align="center">
</td>
<td width="167.999958" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Identification No.)</font></p align="center">
</td>
</tr>
</table></div>
<p>
</p align="center">
<div align="center" style="position:relative; left: 0"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="238.666607" colspan="1" rowspan="1" >
<p align="center">
<font size="2">2200 Wilson Blvd.</font></p align="center">
</td>
<td width="107.999973" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="238.666607" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Suite 102-316</font></p align="center">
</td>
<td width="107.999973" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="238.666607" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Arlington, VA</font></p align="center">
</td>
<td width="107.999973" colspan="1" rowspan="1" >
<p align="center">
<font size="2">22201</font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="238.666607" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(Address of principal executive
offices)</font></p align="center">
</td>
<td width="107.999973" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(Zip Code)</font></p align="center">
</td>
</tr>
</table></div>
<p>
<p align="center">
<font size="2">Registrant&#8217;s telephone number, including area code: (703)
526-0400</font><p align="center">
<font size="2">(Former name or former address, if changed since last
report.)</font><p>
<font size="2">Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</font><p>
<font size="2">[&nbsp;&nbsp;] Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)</font><br><font size="2">[&nbsp;&nbsp;]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)</font><br><font size="2">[&nbsp;&nbsp;] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))</font><br><font size="2">[&nbsp;&nbsp;] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))</font></p align="center">
<div align="center" color="#000080" style="position:relative; left: -5"><b>1</b><hr size="3" color="#999999" STYLE="page-break-after: always"> &nbsp; </div><p>
<p>
<font size="2"><b>Item 5.02 &nbsp;&nbsp;Departure of Directors or Principal
Officers; Election of Directors; Appointment of Principal Officers</b></font><p>
<font size="2">Champions Biotechnology, Inc., (the &#8220;Company&#8221;)
announced that effective October 22, 2007, James Martell resigned as Chairman of
the Board of Directors.  He retains his positions of President, Chief Executive
Officer and Director of the Company. </font><p>
<font size="2">Effective October 22, 2007 Dr. David Sidransky was appointed the
Chairman of the Board of Directors. Since 1994, Dr. David Sidransky, age 47, has
been the Director of the Head and Neck Cancer Research Division at Johns Hopkins
University School of Medicine, Baltimore, Maryland. He is a Professor of
Oncology, Otolaryngology, Cellular &amp; Molecular Medicine, Urology, Genetics,
and Pathology at John Hopkins University and Hospital. Dr. Sidransky is
certified in Internal Medicine and Medical Oncology by the American Board of
Medicine. Dr. Sidransky has served as Vice Chairman of the Board of Directors,
and presently is a director of ImClone. He is a Vice Chairman of Alfacell and
serves on the Board of Directors of Xenomics. He is serving and has served on
scientific advisory boards of MedImmune, Roche, Amgen and Veridex, LLC (a
Johnson &amp; Johnson diagnostic company), among others.  </font><p>
<font size="2">The text of the related press release, which is attached as
Exhibit&nbsp;99.1, is incorporated by reference herein in its
entirety.</font><p>
<!--<a name="_Toc147111982"></a>--><font size="2"><b>Item 9.01. Financial Statements
and Exhibits</b></font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press
release October 23, 2007</font><p align="center">
<font size="2"><b>SIGNATURES</b></font><p>
<font size="2">Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be</font>
<font size="2">signed on its behalf by the undersigned thereunto duly
authorized.</font></p>
<div style="position:relative; left: 0"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="359.999910" colspan="1" rowspan="1" >
<p>
<font size="2">Date: October 23, 2007</font></p>
</td>
<td width="277.333264" colspan="2" rowspan="1" >
<p>
<font size="2">CHAMPIONS BIOTECHNOLOGY, INC.</font></p>
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="3" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="359.999910" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="23.999994" colspan="1" rowspan="1" >
<p>
<font size="2">By:</font></p>
</td>
<td width="253.333270" colspan="1" rowspan="1" >
<p>
<font size="2"><u>/s/&nbsp;&nbsp;James Martell</u></font></p>
</td>
</tr>
<tr valign="top">
<td width="359.999910" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="23.999994" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;</font></p>
</td>
<td width="253.333270" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;James Martell</font></p>
</td>
</tr>
<tr valign="top">
<td width="359.999910" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="23.999994" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;</font></p>
</td>
<td width="253.333270" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer and
President</font></p>
</td>
</tr>
</table></div>
<p>
</p align="center">
<div align="center" color="#000080" style="position:relative; left: -5"><b>2</b><hr size="3" color="#999999" STYLE="page-break-after: always"> &nbsp; </div><p>
</p>


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>cbi8k-sidranskypressrel.htm
<DESCRIPTION>PRESS RELEASE 10-23-2007
<TEXT>
<html>
<head><meta content="text/html; charset=iso-8859-1">
<title>  CHAMPIONS  Biotechnology, Inc</title>
</head>

<body >
<ul>
</ul>

<p align="right">
<font size="2">Exhibit 99.1</font><p align="center">
<font size="4" color="#ff0000">CHAMPIONS  Biotechnology,
Inc.</font><br><font size="2">2200 Wilson Boulevard, Suite
102-316</font><br><font size="2">Arlington, VA 22201,
USA</font><p align="center">
<b>Dr. David Sidransky appointed Chairman of Champions Biotechnology,
Inc.</b><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Arlington, VA., October
23, 2007. Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a
development stage biotechnology company, announced today the appointment of Dr.
David Sidransky, Director of the Head and Neck Cancer Research Division at Johns
Hopkins University School of Medicine, to serve as Chairman of the Board,
replacing James Martell who has served in that capacity since 1991. Dr.
Sidransky was appointed to serve on the Company&#8217;s Board of Directors in
August 2007. He is the largest shareholder of Champions Biotechnology.</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr. Sidransky, 47, is a
renowned oncologist and research scientist named and profiled by TIME magazine
in 2001 as one of the top physicians and scientists in America, recognized for
his work with early detection of cancer. He is Professor of Oncology,
Otolaryngology, Cellular &amp; Molecular Medicine, Urology, Genetics, and
Pathology at John Hopkins University and Hospital. Dr. Sidransky is one of the
five most highly cited researchers in clinical and medical journals in the
world, in the field of oncology during the past decade, with over 300
peer-reviewed publications. He has contributed more than 40 cancer reviews and
chapters. Dr. Sidransky is a founder of a number of biotechnology companies and
holds numerous biotechnology patents. </font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr. Sidransky has
served as Vice Chairman of the Board of Directors, and presently is a director
of ImClone. He is a Vice Chairman of Alfacell and serves on the Board of
Directors of Xenomics. He is serving and has served on scientific advisory
boards of MedImmune, Roche, Amgen and Veridex, LLC (a Johnson &amp; Johnson
diagnostic company), among others.  </font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr. Sidransky serves as
Director (2005-2008) of American Association for Cancer Research (AACR).  He was
the chairperson of AACR International Conferences (2006 and 2007) on Molecular
Diagnostics in Cancer Therapeutic Development: <i>Maximizing Opportunities for
Individualized Treatment</i>.</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr. Sidransky is the
recipient of a number of awards and honors, including the 1997 Sarstedt
International Prize from the German Society of Clinical Chemistry, the 1998
Alton Ochsner Award Relating Smoking and Health by the American College of Chest
Physicians and the 2004 Hinda and Richard Rosenthal Award from the American
Association of Cancer Research.</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;I am highly
honored by the great privilege of having Dr. Sidransky lead the company into the
future as its Chairman&#8221; said James Martell, President and CEO of Champions
Biotechnology. &#8220;Dr. Sidransky is a creative, out-of-the box thinker with
wide-ranging academic and business background and extensive contacts within the
pharmaceutical industry, academia and government. He will provide the vision,
direction, drive and inspiration to grow our Company into what we hope will be
one of the leading biotechnology players in the world, in the fight against
disease.&#8221;   </font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Champions Biotechnology
is actively engaged, as stated in the Company&#8217;s most recent 10-QSB filing,
in pursuit of long term funding, additional opportunities to grow and strengthen
the Company, development of management team, selection and appointment of new
members to the Board of Directors and formation of a Scientific Advisory Board.
The Company looks forward to reporting updates regarding any material events and
corporate changes in the future.</font></p align="center">
<div align="center" color="#000080" style="position:relative; left: -5"><b>1</b><hr size="3" color="#999999" STYLE="page-break-after: always"> &nbsp; </div><p>
<p>
<font size="2"><i>About Champions Biotechnology, Inc. </i></font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Champions Biotechnology
is a twenty two year old publicly traded company that beginning in January 2007,
changed its business direction to focus on biotechnology. The Company is engaged
in the acquisition and early stage development of a portfolio of new therapeutic
drug candidates, in the acquisition and development of novel technologies and in
providing administrative services in the field of oncology that the Company
hopes will improve methods of and approaches to disease treatment.  </font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Champions Biotechnology
plans to develop a portfolio of new therapeutic drug candidates through
pre-clinical trials and possibly early phase ("first in man") clinical trials.
If therapeutic drug candidates reach this early stage of development, Champions
Biotechnology intends to sell, partner with, or license them to pharmaceutical
and/or biotechnology companies, as appropriate. Management believes this
strategy will enable Champions Biotechnology to leverage the competencies of
these partners or licensees to maximize Champions Biotechnology&#8217;s return
on investment in a relatively short time frame. Champions Biotechnology believes
that this model is unlike that of typical new biotechnology companies that look
to bring the process of drug development through all phases of discovery,
development, regulatory approvals, and marketing, which requires a very large
financial commitment and a long time, typically more than a decade, to
realize.</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2007,
Champions Biotechnology acquired the patent rights to two Benzoylphenylurea
(BPU) sulfur analog compounds that have shown promising potent activity against
prostate and pancreatic cancer cell lines. </font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2007, Champions
Biotechnology acquired Biomerk Inc. a company focused on generating a novel
preclinical platform of human cancer tumor immune-deficient mice xenografts
(Biomerk Tumorgrafts&#8482;).  Biomerk Tumorgrafts&#8482;, unlike standard cell
line derived xenografts, are implanted directly from primary human cancer tumors
and never passaged in cell tissue culture. Champions Biotechnology believes that
these xenografts more closely reflect human cancer biology and are more
predictive of clinical outcome. Champions Biotechnology believes that it as well
as biotechnology and  pharmaceutical companies, as part of their drug discovery
and post marketing efforts, may benefit from utilizing services that are more
predictive and that might provide for a faster and less expensive path for drug
approval. These services will utilize Biomerk Tumorgrafts&#8482; to evaluate
tumor sensitivity/resistance to various single and combination standard and
novel chemotherapy agents.</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This press release
contains "forward-looking statements" (within the meaning of the Private
Securities Litigation Act of 1995) that inherently involve risk and
uncertainties. Champions Biotechnology generally uses words such as "believe,"
"may," "could," "will," "intend," "expect," "anticipate," "plan," and similar
expressions to identify forward-looking statements. One should not place undue
reliance on these forward-looking statements. Champions Biotechnology&#8217;s
actual results could differ materially from those anticipated in the
forward-looking statements for many unforeseen factors, which may include, but
are not limited to, changes in general economic conditions, the ongoing threat
of terrorism, ability to have access to financing sources on reasonable terms
and other risks that are described in this document. Although Champions
Biotechnology believes the expectations reflected in the forward-looking
statements are reasonable, they relate only to events as of the date on which
the statements are made, and Champions Biotechnology&#8217;s future results,
levels of activity, performance or achievements may not meet these expectations.
Champions Biotechnology does not intend to update any of the forward-looking
statements after the date of this press release to conform these statements to
actual results or to changes in Champions Biotechnology&#8217;s expectations,
except as required by law. </font><p>
<font size="2">Contact: James Martell (703) - 526-0400
</font><font size="2" color="#0000ff"><u>www,championsbiotechnology,com</u></font><font size="2">
</font></p align="center">
<div align="center" color="#000080" style="position:relative; left: -5"><b>2</b><hr size="3" color="#999999" STYLE="page-break-after: always"> &nbsp; </div><p>
</p>


</body>

</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
